The blockbuster cholesterol drug Vytorin failed to improve a rare heart valve condition called aortic stenosis and seemed to increase rates of cancer, a new study says, dealing another blow to the top-selling drug and its makers, Merck and Schering-Plough .
FORBES: Another Blow For Merck And Schering